The DOI matches its Crossref record; 166 of the 166 references it cites were found in a registry or an index.
Pushing the limits of targeted therapy in chronic myeloid leukaemia
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
A role for Wnt signalling in self-renewal of haematopoietic stem cells
Reya, T., Duncan, A. W., Ailles, L., Domen, J., Scherer, D. C., Willert, K., Hintz, L., Nusse, R., & Weissman, I. L. (2003) · Nature · doi:10.1038/nature01593 · Cited by 2,159
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912614 · Cited by 1,678
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
Mahon, F.-X., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70233-3 · Cited by 1,550
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040258 · Cited by 1,485
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Baccarani, M. (2006) · Blood · doi:10.1182/blood-2006-02-005686 · Cited by 1,277
O'Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.028 · Cited by 1,259
Self-citationHughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218
Hughes, T. (2006) · Blood · doi:10.1182/blood-2006-01-0092 · Cited by 1,199
Graham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181
BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
Mullighan, C. G., Miller, C. B., Radtke, I., Phillips, L. A., Dalton, J., Ma, J., White, D., Hughes, T. P., Le Beau, M. M., Pui, C.-H., et al. (2008) · Nature · doi:10.1038/nature06866 · Cited by 1,072
O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036
Self-citationNagar, B., Bornmann, W. G., Pellicena, P., Schindler, T. H., Veach, D. R., Miller, W. T., Clarkson, B. D., & Kuriyan, J. (2002) · PubMed · Cited by 923
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 906
Hematopoiesis: a human perspective
Doulatov, S., Notta, F., Laurenti, E., & Dick, J. E. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.01.006 · Cited by 895
Gastrointestinal stromal tumours: origin and molecular oncology
Corless, C. L., Barnett, C. M., & Heinrich, M. C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3143 · Cited by 891
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann, W., Clarkson, B., Superti-Furga, G., & Kuriyan, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00194-6 · Cited by 879
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
Ren, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1567 · Cited by 878
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
Zhao, C., Chen, A., Jamieson, C. H., Fereshteh, M., Abrahamsson, A., Blum, J., Kwon, H. Y., Kim, J., Chute, J. P., Rizzieri, D., et al. (2009) · Nature · doi:10.1038/nature07737 · Cited by 869
Hochhaus, A., O'Brien, S. G., Guilhot, F., Druker, B. J., Branford, S., Foroni, L., Goldman, J. M., Müller, M. C., Radich, J. P., Rudoltz, M., et al. (2009) · Leukemia · doi:10.1038/leu.2009.38 · Cited by 856
Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765
Self-citationHuntly, B. J. P., Shigematsu, H., Deguchi, K., Lee, B. H., Mizuno, S., Duclos, N., Rowan, R., Amaral, S., Curley, D., Williams, I. R., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.015 · Cited by 697
Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation
Bhardwaj, G., Murdoch, B., Wu, D., Baker, D. P., Williams, K. P., Chadwick, K., Ling, L. E., Karanu, F. N., & Bhatia, M. (2001) · Nature Immunology · doi:10.1038/84282 · Cited by 677
Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R., & Talpaz, M. (2003) · Blood · doi:10.1182/blood.v101.2.690 · Cited by 663
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Apperley, J. F. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70342-x · Cited by 643
O'Hare, T., Eide, C. A., & Deininger, M. W. N. (2007) · Blood · doi:10.1182/blood-2007-03-066936 · Cited by 641
Self-citationCopland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L. (2006) · Blood · doi:10.1182/blood-2005-07-2947 · Cited by 635
Chronic myeloid leukaemia as a model of disease evolution in human cancer
Melo, J. V., & Barnes, D. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2147 · Cited by 623
Deininger, M., O'Brien, S. G., Guilhot, F., Goldman, J. M., Hochhaus, A., Hughes, T. P., Radich, J. P., Hatfield, A. K., Mone, M., Filian, J., et al. (2009) · Blood · doi:10.1182/blood.v114.22.1126.1126 · Cited by 616
Self-citationMechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL
Azam, M., Latek, R. R., & Daley, G. Q. (2003) · Cell · doi:10.1016/s0092-8674(03)00190-9 · Cited by 613
Kantarjian, H. M., Shah, N. P., Cortes, J. E., Baccarani, M., Agarwal, M. B., Undurraga, M. S., Wang, J., Kassack Ipiña, J. J., Kim, D.-W., Ogura, M., et al. (2012) · Blood · doi:10.1182/blood-2011-08-376087 · Cited by 610
Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors
Zhang, J., Adrián, F. J., Jahnke, W., Cowan-Jacob, S. W., Li, A. G., Iacob, R. E., Sim, T., Powers, J., Dierks, C., Sun, F., et al. (2010) · Nature · doi:10.1038/nature08675 · Cited by 597
Loss of β-Catenin Impairs the Renewal of Normal and CML Stem Cells In Vivo
Zhao, C., Blum, J., Chen, A., Kwon, H. Y., Jung, S. H., Cook, J. M., Lagoo, A., & Reya, T. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.11.003 · Cited by 592
Soverini, S., Hochhaus, A., Nicolini, F. E., Gruber, F., Lange, T., Saglio, G., Pane, F., Müller, M. C., Ernst, T., Rosti, G., et al. (2011) · Blood · doi:10.1182/blood-2010-12-326405 · Cited by 589
Gene expression changes associated with progression and response in chronic myeloid leukemia
Radich, J. P., Dai, H., Mao, M., Oehler, V., Schelter, J., Druker, B., Sawyers, C., Shah, N., Stock, W., Willman, C. L., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510423103 · Cited by 583
TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
Naka, K., Hoshii, T., Muraguchi, T., Tadokoro, Y., Ooshio, T., Kondo, Y., Nakao, S., Motoyama, N., & Hirao, A. (2010) · Nature · doi:10.1038/nature08734 · Cited by 583
Bellodi, C., Lidonnici, M. R., Hamilton, A., Helgason, G. V., Soliera, A. R., Ronchetti, M., Galavotti, S., Young, K. W., Selmi, T., Yacobi, R., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci35660 · Cited by 570
Eiring, A. M., Harb, J. G., Neviani, P., Garton, C., Oaks, J. J., Spizzo, R., Liu, S., Schwind, S., Santhanam, R., Hickey, C. J., et al. (2010) · Cell · doi:10.1016/j.cell.2010.01.007 · Cited by 560
Self-citationRousselot, P., Huguet, F., Rea, D., Legros, L., Cayuela, J. M., Maarek, O., Blanchet, O., Marit, G., Gluckman, E., Reiffers, J., et al. (2007) · Blood · doi:10.1182/blood-2006-03-011239 · Cited by 538
PML targeting eradicates quiescent leukaemia-initiating cells
Ito, K., Bernardi, R., Morotti, A., Matsuoka, S., Saglio, G., Ikeda, Y., Rosenblatt, J., Avigan, D. E., Teruya-Feldstein, J., & Pandolfi, P. P. (2008) · Nature · doi:10.1038/nature07016 · Cited by 538
Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation
Dierks, C., Beigi, R., Guo, G.-R., Zirlik, K., Stegert, M. R., Manley, P., Trussell, C., Schmitt-Graeff, A., Landwerlin, K., Veelken, H., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.08.003 · Cited by 517
Kantarjian, H. M., Hochhaus, A., Saglio, G., De Souza, C., Flinn, I. W., Stenke, L., Goh, Y.-T., Rosti, G., Nakamae, H., Gallagher, N. J., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70201-7 · Cited by 513
A Myristoyl/Phosphotyrosine Switch Regulates c-Abl
Hantschel, O., Nagar, B., Guettler, S., Kretzschmar, J., Dorey, K., Kuriyan, J., & Superti-Furga, G. (2003) · Cell · doi:10.1016/s0092-8674(03)00191-0 · Cited by 480
Neviani, P., Santhanam, R., Trotta, R., Notari, M., Blaser, B. W., Liu, S., Mao, H., Chang, J. S., Galietta, A., Uttam, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.015 · Cited by 476
Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells
Notta, F., Mullighan, C. G., Wang, J. C. Y., Poeppl, A., Doulatov, S., Phillips, L. A., Ma, J., Minden, M. D., Downing, J. R., & Dick, J. E. (2011) · Nature · doi:10.1038/nature09733 · Cited by 463
Cortes, J. E., Kantarjian, H. M., Brümmendorf, T. H., Kim, D.-W., Turkina, A. G., Shen, Z.-X., Pasquini, R., Khoury, H. J., Arkin, S., Volkert, A., et al. (2011) · Blood · doi:10.1182/blood-2011-05-355594 · Cited by 463
Foà, R., Vitale, A., Vignetti, M., Meloni, G., Guarini, A., De Propris, M. S., Elia, L., Paoloni, F., Fazi, P., Cimino, G., et al. (2011) · Blood · doi:10.1182/blood-2011-05-351403 · Cited by 462
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
Hamilton, A., Helgason, G. V., Schemionek, M., Zhang, B., Myssina, S., Allan, E. K., Nicolini, F. E., Müller-Tidow, C., Bhatia, R., Brunton, V. G., et al. (2012) · Blood · doi:10.1182/blood-2010-12-326843 · Cited by 435
Gambacorti-Passerini, C., Antolini, L., Mahon, F.-X., Guilhot, F., Deininger, M., Fava, C., Nagler, A., Della Casa, C. M., Morra, E., Abruzzese, E., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr060 · Cited by 429
Self-citationShah, N. P., Skaggs, B. J., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., & Sawyers, C. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30890 · Cited by 418
Activation of tyrosine kinases by mutation of the gatekeeper threonine
Azam, M., Seeliger, M. A., Gray, N. S., Kuriyan, J., & Daley, G. Q. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1486 · Cited by 411
Li, L., Wang, L., Li, L., Wang, Z., Ho, Y., McDonald, T., Holyoake, T. L., Chen, W., & Bhatia, R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.020 · Cited by 410
Hu, Y., Liu, Y., Pelletier, S., Buchdunger, E., Warmuth, M., Fabbro, D., Hallek, M., Van Etten, R. A., & Li, S. (2004) · Nature Genetics · doi:10.1038/ng1343 · Cited by 405
Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
Redaelli, S., Piazza, R., Rostagno, R., Magistroni, V., Perini, P., Marega, M., Gambacorti-Passerini, C., & Boschelli, F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8853 · Cited by 399
Chronic myeloid leukemia: mechanisms of blastic transformation
Perrotti, D., Jamieson, C., Goldman, J., & Skorski, T. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41246 · Cited by 397
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
Preudhomme, C., Guilhot, J., Nicolini, F. E., Guerci-Bresler, A., Rigal-Huguet, F., Maloisel, F., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1004095 · Cited by 392
Allosteric inhibitors of Bcr-abl–dependent cell proliferation
Adrián, F. J., Ding, Q., Sim, T., Velentza, A., Sloan, C., Liu, Y., Zhang, G., Hur, W., Ding, S., Manley, P., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio760 · Cited by 381
Puttini, M., Coluccia, A. M. L., Boschelli, F., Cleris, L., Marchesi, E., Donella-Deana, A., Ahmed, S., Redaelli, S., Piazza, R., Magistroni, V., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1199 · Cited by 375
Huang, W.-S., Metcalf, C. A., Sundaramoorthi, R., Wang, Y., Zou, D., Thomas, R. M., Zhu, X., Cai, L., Wen, D., Liu, S., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100395q · Cited by 369
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value
Walker, B. A., Leone, P. E., Chiecchio, L., Dickens, N. J., Jenner, M. W., Boyd, K. D., Johnson, D. C., Gonzalez, D., Dagrada, G. P., Protheroe, R. K. M., et al. (2010) · Blood · doi:10.1182/blood-2010-04-279596 · Cited by 365
Jiang, X., Zhao, Y., Smith, C., Gasparetto, M., Turhan, A., Eaves, A., & Eaves, C. (2007) · Leukemia · doi:10.1038/sj.leu.2404609 · Cited by 359
Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells
Krause, D. S., Lazarides, K., von Andrian, U. H., & Van Etten, R. A. (2006) · Nature Medicine · doi:10.1038/nm1489 · Cited by 349
Neviani, P., Santhanam, R., Oaks, J. J., Eiring, A. M., Notari, M., Blaser, B. W., Liu, S., Trotta, R., Muthusamy, N., Gambacorti-Passerini, C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31095 · Cited by 335
Self-citationMarin, D., Milojkovic, D., Olavarria, E., Khorashad, J. S., de Lavallade, H., Reid, A. G., Foroni, L., Rezvani, K., Bua, M., Dazzi, F., et al. (2008) · Blood · doi:10.1182/blood-2008-06-162388 · Cited by 328
Khoury, H. J., Cortes, J. E., Kantarjian, H. M., Gambacorti-Passerini, C., Baccarani, M., Kim, D.-W., Zaritskey, A., Countouriotis, A., Besson, N., Leip, E., et al. (2012) · Blood · doi:10.1182/blood-2011-11-390120 · Cited by 324
Burgess, M. R., Skaggs, B. J., Shah, N. P., Lee, F. Y., & Sawyers, C. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409770102 · Cited by 313
Hughes, T., Saglio, G., Branford, S., Soverini, S., Kim, D.-W., Müller, M. C., Martinelli, G., Cortes, J., Beppu, L., Gottardi, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.8230 · Cited by 306
BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance
Koptyra, M., Falinski, R., Nowicki, M. O., Stoklosa, T., Majsterek, I., Nieborowska-Skorska, M., Blasiak, J., & Skorski, T. (2006) · Blood · doi:10.1182/blood-2005-07-2815 · Cited by 298
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia
Chen, Y., Hu, Y., Zhang, H., Peng, C., & Li, S. (2009) · Nature Genetics · doi:10.1038/ng.389 · Cited by 293
Essafi, A., Fernández de Mattos, S., Hassen, Y. A. M., Soeiro, I., Mufti, G. J., Thomas, N. S. B., Medema, R. H., & Lam, E. W.-F. (2005) · Oncogene · doi:10.1038/sj.onc.1208421 · Cited by 293
Zhou, T., Commodore, L., Huang, W., Wang, Y., Thomas, M., Keats, J., Xu, Q., Rivera, V. M., Shakespeare, W. C., Clackson, T., et al. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2010.01054.x · Cited by 287
Oda, T., Heaney, C., Hagopian, J. R., Okuda, K., Griffin, J. D., & Druker, B. J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31596-x · Cited by 272
Hu, Y., Swerdlow, S., Duffy, T. M., Weinmann, R., Lee, F. Y., & Li, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606509103 · Cited by 271
Zhang, B., Strauss, A. C., Chu, S., Li, M., Ho, Y., Shiang, K.-D., Snyder, D. S., Huettner, C. S., Shultz, L., Holyoake, T., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.011 · Cited by 256
Clark, R. E., Dodi, I. A., Hill, S. C., Lill, J. R., Aubert, G., Macintyre, A. R., Rojas, J., Bourdon, A., Bonner, P. L. R., Wang, L., et al. (2001) · Blood · doi:10.1182/blood.v98.10.2887 · Cited by 253
Bocchia, M., Gentili, S., Abruzzese, E., Fanelli, A., Iuliano, F., Tabilio, A., Amabile, M., Forconi, F., Gozzetti, A., Raspadori, D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17945-8 · Cited by 247
Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation
Abrahamsson, A. E., Geron, I., Gotlib, J., Dao, K.-H. T., Barroga, C. F., Newton, I. G., Giles, F. J., Durocher, J., Creusot, R. S., Karimi, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900189106 · Cited by 246
Chu, S., McDonald, T., Lin, A., Chakraborty, S., Huang, Q., Snyder, D. S., & Bhatia, R. (2011) · Blood · doi:10.1182/blood-2010-12-327437 · Cited by 245
Heidel, F. H., Bullinger, L., Feng, Z., Wang, Z., Neff, T. A., Stein, L., Kalaitzidis, D., Lane, S. W., & Armstrong, S. A. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.02.017 · Cited by 225
Bcr‐Abl stabilizes β‐catenin in chronic myeloid leukemia through its tyrosine phosphorylation
Coluccia, A. M. L., Vacca, A., Duñach, M., Mologni, L., Redaelli, S., Bustos, V. H., Benati, D., Pinna, L. A., & Gambacorti‐Passerini, C. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601485 · Cited by 217
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
Burchert, A., Wang, Y., Cai, D., von Bubnoff, N., Paschka, P., Müller-Brüsselbach, S., Ottmann, O. G., Duyster, J., Hochhaus, A., & Neubauer, A. (2005) · Leukemia · doi:10.1038/sj.leu.2403898 · Cited by 213
Jin, L., Tabe, Y., Konoplev, S., Xu, Y., Leysath, C. E., Lu, H., Kimura, S., Ohsaka, A., Rios, M.-B., Calvert, L., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0042 · Cited by 209
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia
Cathcart, K., Pinilla-Ibarz, J., Korontsvit, T., Schwartz, J., Zakhaleva, V., Papadopoulos, E. B., & Scheinberg, D. A. (2004) · Blood · doi:10.1182/blood-2003-03-0954 · Cited by 208
Chan, W. W., Wise, S. C., Kaufman, M. D., Ahn, Y. M., Ensinger, C. L., Haack, T., Hood, M. M., Jones, J., Lord, J. W., Lu, W. P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.003 · Cited by 208
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR–ABL1 kinase inhibition
Duy, C., Hurtz, C., Shojaee, S., Cerchietti, L., Geng, H., Swaminathan, S., Klemm, L., Kweon, S.-M., Nahar, R., Braig, M., et al. (2011) · Nature · doi:10.1038/nature09883 · Cited by 204
Chomel, J.-C., Bonnet, M.-L., Sorel, N., Bertrand, A., Meunier, M.-C., Fichelson, S., Melkus, M., Bennaceur-Griscelli, A., Guilhot, F., & Turhan, A. G. (2011) · Blood · doi:10.1182/blood-2011-02-335497 · Cited by 197
Hedgehog Signaling Is Dispensable for Adult Hematopoietic Stem Cell Function
Gao, J., Graves, S., Koch, U., Liu, S., Jankovic, V., Buonamici, S., El Andaloussi, A., Nimer, S. D., Kee, B. L., Taichman, R., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.03.015 · Cited by 193
HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells
Zhang, H., Li, H., Xi, H. S., & Li, S. (2012) · Blood · doi:10.1182/blood-2011-10-387381 · Cited by 191
Järås, M., Johnels, P., Hansen, N., Ågerstam, H., Tsapogas, P., Rissler, M., Lassen, C., Olofsson, T., Bjerrum, O. W., Richter, J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004408107 · Cited by 185
Targeting the Wnt/β-catenin signaling pathway in human cancers
Yao, H., Ashihara, E., & Maekawa, T. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.577418 · Cited by 184
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia
Hantschel, O., Warsch, W., Eckelhart, E., Kaupe, I., Grebien, F., Wagner, K.-U., Superti-Furga, G., & Sexl, V. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.775 · Cited by 183
Wnt/Ca2+/NFAT Signaling Maintains Survival of Ph+ Leukemia Cells upon Inhibition of Bcr-Abl
Gregory, M. A., Phang, T. L., Neviani, P., Alvarez-Calderon, F., Eide, C. A., O'Hare, T., Zaberezhnyy, V., Williams, R. T., Druker, B. J., Perrotti, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.025 · Cited by 180
Self-citationTakahashi, N., Miura, I., Saitoh, K., & Miura, A. B. (1998) · Blood · doi:10.1182/blood.v92.12.4758 · Cited by 179
Hurtz, C., Hatzi, K., Cerchietti, L., Braig, M., Park, E., Kim, Y.-M., Herzog, S., Ramezani-Rad, P., Jumaa, H., Müller, M. C., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110304 · Cited by 177
Vianello, F., Villanova, F., Tisato, V., Lymperi, S., Ho, K.-K., Gomes, A. R., Marin, D., Bonnet, D., Apperley, J., Lam, E. W. F., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.017178 · Cited by 176
Soverini, S., Gnani, A., Colarossi, S., Castagnetti, F., Abruzzese, E., Paolini, S., Merante, S., Orlandi, E., de Matteis, S., Gozzini, A., et al. (2009) · Blood · doi:10.1182/blood-2009-01-197186 · Cited by 175
Garg, R. J., Kantarjian, H., O'Brien, S., Quintás-Cardama, A., Faderl, S., Estrov, Z., & Cortes, J. (2009) · Blood · doi:10.1182/blood-2009-05-221531 · Cited by 164
Chu, S., Holtz, M., Gupta, M., & Bhatia, R. (2004) · Blood · doi:10.1182/blood-2003-04-1271 · Cited by 163
Autoinhibition of Bcr-Abl through Its SH3 Domain
Smith, K. M., Yacobi, R., & Van Etten, R. A. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00274-0 · Cited by 162
Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis
Grebien, F., Hantschel, O. D., Wojcik, J. B., Kaupe, I., Kovačic, B., Wyrzucki, A. M., Gish, G. D., Cerny‐Reiterer, S., Koide, A., Beug, H., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.046 · Cited by 152
Jabbour, E. J., Kantarjian, H. M., O'Brien, S. M., Shan, J., Quintás‐Cardama, A., Faderl, S. H., Garcia‐Manero, G., Ravandi, F., Rios, M. B., & Cortes, J. E. (2011) · Blood · doi:10.1182/blood-2011-04-348110 · Cited by 151
Levinson, N. M., & Boxer, S. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029828 · Cited by 149
Wang, Y., Cai, D., Brendel, C. A., Barett, C., Erben, P., Manley, P. W., Hochhaus, A., Neubauer, A., & Burchert, A. (2006) · Blood · doi:10.1182/blood-2006-08-040022 · Cited by 147
Jabbour, E. J., Kantarjian, H. M., Jones, D. M., Breeden, M., Garcia‐Manero, G., O'Brien, S. M., Ravandi, F., Borthakur, G. M., & Cortes, J. E. (2008) · Blood · doi:10.1182/blood-2007-11-123950 · Cited by 147
Targeting hedgehog in hematologic malignancy
Irvine, D. A., & Copland, M. (2012) · Blood · doi:10.1182/blood-2011-10-383752 · Cited by 145
Schmidt, T., Masouleh, B. K., Loges, S., Cauwenberghs, S., Fraisl, P., Maes, C., Jonckx, B., Keersmaecker, K. D., Kleppe, M., Tjwa, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.007 · Cited by 140
Lucas, C. M., Harris, R. J., Giannoudis, A., Copland, M., Slupsky, J. R., & Clark, R. E. (2011) · Blood · doi:10.1182/blood-2010-08-304477 · Cited by 138
Goldman, J. M., Majhail, N. S., Klein, J. P., Wang, Z., Sobocinski, K. A., Arora, M., Horowitz, M. M., & Rizzo, J. D. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7757 · Cited by 137
Burchert, A., Wölfl, S., Schmidt, M., Brendel, C. A., Denecke, B., Cai, D., Odyvanova, L., Lahaye, T., Müller, M. C., Berg, T., et al. (2002) · Blood · doi:10.1182/blood-2002-02-0659 · Cited by 137
Trageser, D., Iacobucci, I., Nahar, R. R., Duy, C., von Levetzow, G., Klemm, L., Park, E., Schuh, W., Gruber, T. A., Herzog, S., et al. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090004 · Cited by 136
McWeeney, S. K., Pemberton, L. C., Loriaux, M., Vartanian, K. A., Willis, S. G., Yochum, G. S., Wilmot, B., Turpaz, Y., Pillai, R., Druker, B. J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-210732 · Cited by 128
Self-citationSamanta, A. K., Chakraborty, S. N., Wang, Y., Kantarjian, H. M., Sun, X., Hood, J. D., Perrotti, D., & Arlinghaus, R. B. (2009) · Oncogene · doi:10.1038/onc.2009.7 · Cited by 127
Exploiting synthetic lethal interactions for targeted cancer therapy
Reinhardt, H. C., Jiang, H., Hemann, M. T., & Yaffe, M. B. (2009) · Cell Cycle · doi:10.4161/cc.8.19.9626 · Cited by 125
Packer, L., Rana, S., Hayward, R., O’Hare, T., Eide, C. A., Rebocho, A. P., Heidorn, S. J., Zabriskie, M. S., Niculescu‐Duvaz, I., Druker, B. J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.004 · Cited by 125
Self-citationJahnke, W., Grotzfeld, R. M., Pellé, X., Strauss, A., Fendrich, G., Cowan‐Jacob, S. W., Cotesta, S., Fabbro, D., Furet, P., Mestan, J., et al. (2010) · Journal of the American Chemical Society · doi:10.1021/ja101837n · Cited by 123
Gioia, R., Leroy, C., Drullion, C., Lagarde, V., Étienne, G., Dulucq, S., Lippert, É., Roche, S., Mahon, F., & Pasquet, J. (2011) · Blood · doi:10.1182/blood-2010-10-313692 · Cited by 118
Eide, C. A., Adrian, L. T., Tyner, J. W., Partlin, M. M., Anderson, D. J., Wise, S., Smith, B. D., Petillo, P. A., Flynn, D. L., Deininger, M. W., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3224 · Cited by 115
Self-citationBcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis
Sun, H., Kapuria, V., Peterson, L. F., Fang, D., Bornmann, W. G., Bartholomeusz, G. A., Talpaz, M., & Donato, N. J. (2011) · Blood · doi:10.1182/blood-2010-03-276477 · Cited by 112
Schürch, C. M., Riether, C., Matter, M. S., Tzankov, A., & Ochsenbein, A. F. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45977 · Cited by 110
Petzer, A., Eaves, C. J., Lansdorp, P., Ponchio, L., Barnett, M. J., & Eaves, A. (1996) · Blood · doi:10.1182/blood.v88.6.2162.bloodjournal8862162 · Cited by 107
Traer, E. A., MacKenzie, R. J., Snead, J. L., Agarwal, A., Eiring, A. M., O’Hare, T., Druker, B. J., & Deininger, M. W. (2011) · Leukemia · doi:10.1038/leu.2011.325 · Cited by 106
Self-citationAlvarado, Y., Kantarjian, H. M., O'Brien, S. M., Faderl, S. H., Borthakur, G. M., Burger, J. A., Wierda, W. G., Garcia‐Manero, G., Shan, J., & Cortes, J. E. (2009) · Cancer · doi:10.1002/cncr.24418 · Cited by 106
Parker, W. T., Lawrence, R., Ho, M., Irwin, D. L., Scott, H. S., Hughes, T. P., & Branford, S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0934 · Cited by 96
How I treat Philadelphia chromosome–positive acute lymphoblastic leukemia
Fielding, A. K. (2010) · Blood · doi:10.1182/blood-2010-01-242750 · Cited by 95
Kumari, A., Brendel, C. A., Hochhaus, A., Neubauer, A., & Burchert, A. (2011) · Blood · doi:10.1182/blood-2010-08-303495 · Cited by 87
Khorashad, J. S., Milojković, D., Mehta, P., Anand, M., Ghorashian, S., Reid, A. G., Melo, V. D., Babb, A., de Lavallade, H., Olavarría, E., et al. (2007) · Blood · doi:10.1182/blood-2007-06-096396 · Cited by 87
Jabbour, E. J., Kantarjian, H. M., O'Brien, S. M., Shan, J., Garcia‐Manero, G., Wierda, W. G., Ravandi, F., Borthakur, G. M., Rios, M. B., & Cortes, J. E. (2010) · Blood · doi:10.1182/blood-2010-07-293977 · Cited by 75
Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
Weisberg, E., Wright, R. D., McMillin, D. W., Mitsiades, C. S., Ray, A., Barrett, R., Adamia, S., Stone, R. M., Galinsky, I. A., Kung, A. L., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2331 · Cited by 74
Wong, S., McLaughlin, J., Cheng, D., Zhang, C., Shokat, K. M., & Witte, O. N. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407061101 · Cited by 72
Weisberg, E., Choi, H. G., Ray, A., Barrett, R., Zhang, J., Sim, T., Zhou, W., Seeliger, M. A., Cameron, M. D., Azam, M., et al. (2010) · Blood · doi:10.1182/blood-2009-11-251751 · Cited by 68
Ramaraj, P., Singh, H., Niu, N., Chu, S., Holtz, M., Yee, J. K., & Bhatia, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3656 · Cited by 68
Dillmann, F., Veldwijk, M. R., Laufs, S., Sperandio, M., Calandra, G., Wenz, F. K., Zeller, W. J., & Früehauf, S. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190903150847 · Cited by 67
Am“B”valent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis
Thaunat, O., Morélon, E., & Defrance, T. (2010) · Blood · doi:10.1182/blood-2010-01-266668 · Cited by 66
Rubbi, L., Titz, B., Brown, L. M., Galvan, E., Komisopoulou, E., Chen, S. S., Low, T., Tahmasian, M., Skaggs, B. J., Müschen, M., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2001314 · Cited by 65
Response definitions and European Leukemianet Management recommendations
Baccarani, M., Castagnetti, F., Gugliotta, G., Palandri, F., & Soverini, S. (2009) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2009.10.001 · Cited by 64
Modi, H., McDonald, T., Chu, S., Yee, J., Forman, S. J., & Bhatia, R. (2007) · Blood · doi:10.1182/blood-2006-06-032490 · Cited by 63
New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check
O’Hare, T., Eide, C. A., & Deininger, M. W. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.6.865 · Cited by 63
Self-citationHeaney, N. B., Pellicano, F., Zhang, B., Crawford, L., Chu, S., Kazmi, S. M. A., Allan, E. K., Jørgensen, H. G., Irvine, A. E., Bhatia, R., et al. (2010) · Blood · doi:10.1182/blood-2008-06-164582 · Cited by 58
Reddiconto, G., Toto, C., Palamà, I. E., Leo, S. D., de Luca, E., Matteis, S. D., Dini, L., Gambacorti-Passerini, C. B., Renzo, N. D., Maffia, M., et al. (2012) · Blood · doi:10.1182/blood-2011-06-361261 · Cited by 56
Esposito, N., Colavita, I., Quintarelli, C., Sica, A., Peluso, A. L., Luciano, L., Picardi, M., Vecchio, L. D., Buonomo, T., Hughes, T. P., et al. (2011) · Blood · doi:10.1182/blood-2011-03-341073 · Cited by 48
Aceves-Luquero, C., Agarwal, A., Callejas‐Valera, J. L., Arias‐González, L., Esparı́s-Ogando, A., del Peso, L., Bellón-Echeverría, I., de la Cruz-Morcillo, M. Á., Galán‐Moya, E. M., Moreno, I., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006124 · Cited by 48
Self-citationJabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.2.161 · Cited by 46
Pellicano, F., Copland, M., Jørgensen, H. G., Mountford, J. C., Leber, B. F., & Holyoake, T. L. (2009) · Blood · doi:10.1182/blood-2009-05-219550 · Cited by 46
Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
Fei, F., Stoddart, S., Müschen, M., Kim, Y.-M., Groffen, J., & Heisterkamp, N. (2010) · Leukemia · doi:10.1038/leu.2009.302 · Cited by 45
(2013) · Blood · doi:10.1182/blood-2013-08-524256 · Cited by 43
Mahon, F., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F. E., Legros, L., Charbonnier, A., Guerci‐Bresler, A., Varet, B. R., et al. (2011) · Blood · doi:10.1182/blood.v118.21.603.603 · Cited by 42
Nair, R. R., Tolentino, J. H. G., Argilagos, R. F., Zhang, L., Pinilla-Ibarz, J. A., & Hazlehurst, L. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.12.002 · Cited by 37
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia
Agarwal, A., Eide, C. A., Harlow, A., Corbin, A. S., Mauro, M. J., Druker, B. J., Corless, C. L., Heinrich, M. C., & Deininger, M. W. (2008) · Leukemia · doi:10.1038/leu.2008.124 · Cited by 36
Self-citationBmi1 reprograms CML B-lymphoid progenitors to become B-ALL–initiating cells
Sengupta, A., Ficker, A. M., Dunn, S. K., Madhu, M., & Cancelas, J. A. (2011) · Blood · doi:10.1182/blood-2011-06-359232 · Cited by 36
Disruption of Bcr-Abl Coiled Coil Oligomerization by Design
Dixon, A. S., Pendley, S. S., Bruno, B. J., Woessner, D. W., Shimpi, A. A., Cheatham, T. E., & Lim, C. S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.264903 · Cited by 34
Mustjoki, S. M., Rohoň, P., Rapakko, K., Jalkanen, S., Koskenvesa, P., Lundán, T., & Porkka, K. (2009) · Leukemia · doi:10.1038/leu.2009.190 · Cited by 19
Weisberg, E., Deng, X., Choi, H. G., Barrett, R., Adamia, S., Ray, A., Moreno, D., Kung, A. L., Gray, N. S., & Griffin, J. D. (2010) · Leukemia · doi:10.1038/leu.2010.107 · Cited by 17
Stagno, F., Stella, S., Berretta, S., Massimino, M., Antolino, A., Giustolisi, R., Messina, A., Raimondo, F. D., & Vigneri, P. G. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.08.008 · Cited by 13
Kim, W., Kim, D., Kim, D., Kweon, I., Kim, S., Goh, H., Park, S.-H., & Lee, J. E. (2009) · Hematological Oncology · doi:10.1002/hon.918 · Cited by 11
Neviani, P., Harb, J. G., Oaks, J. J., Walker, C. J., Santhanam, R., Paisie, C. A., Eiring, A. M., Zhang, B., Perazzona, B., Ma, Y., et al. (2010) · Blood · doi:10.1182/blood.v116.21.515.515 · Cited by 11
Self-citationRousselot, P. H., Cony‐Makhoul, P., Réa, D., Agapé, P., Nicolini, F. E., Legros, L., Tulliez, M., Roy, L., Charbonnier, A., Guilhot, J., et al. (2011) · Blood · doi:10.1182/blood.v118.21.3781.3781 · Cited by 9
Practical Monitoring of Chronic Myelogenous Leukemia: When to Change Treatment
Saglio, G. N., & Fava, C. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0011 · Cited by 8
Walker, C. J., Oaks, J. J., Neviani, P., Harb, J. G., Santhanam, R., Ma, Y., Marcucci, G., Brocklyn, J. R. V., Chen, C., Bittman, R., et al. (2010) · Blood · doi:10.1182/blood.v116.21.2901.2901 · Cited by 4
Herrmann, H., Sadovnik, I., Cerny‐Reiterer, S., Blatt, K., Ghanim, V., Herndlhofer, S., Hoermann, G., Rülicke, T., Willmann, M., Mitterbauer‐Hohendanner, G., et al. (2011) · Blood · doi:10.1182/blood.v118.21.961.961 · Cited by 3
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024
Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
Moslehi, J. J., & Deininger, M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.4718 · Cited by 443
Self-citationRole of ABL family kinases in cancer: from leukaemia to solid tumours
Greuber, E. K., Smith-Pearson, P., Wang, J., & Pendergast, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3563 · Cited by 432
Zabriskie, M. S., Eide, C. A., Tantravahi, S. K., Vellore, N. A., Estrada, J., Nicolini, F. E., Khoury, H. J., Larson, R. A., Konopleva, M., Cortes, J. E., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.006 · Cited by 363
Self-citation
Metadata
- Authors
- O'Hare, T., Zabriskie, M. S., Eiring, A. M., & Deininger, M. W.
- Venue
- Nature Reviews Cancer
- Published
- 2012-07-24
- Volume
- 12
- Issue
- 8
- Pages
- 513-526
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2088110670
- Cited by
- 304
- References
- 166
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.